"Situado en una zona emblemática y bien comunicada de la ciudad, se encuentra el Hospital Quirónsalud Barcelona, un centro con cerca de 70 años de experiencia y que se ha convertido en el referente de la sanidad en el sur de Europa. En un continuo esfuerzo de renovación y adaptación para ofrecer al paciente todo aquello que pueda necesitar, los médicos más cualificados, los medios tecnológicos más innovadores, un trato cálido, personalizado, discreto y una hotelería excepcional."

During the past decade, Hospital Quironsalud Barcelona conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 8 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 7 clinical trials were completed. i.e. 36.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Quironsalud Barcelona" #1 sponsor was "Daiichi Sankyo, Inc." with 5 trials, followed by "Bayer" with 3 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored, "Pfizer" with 3 trials sponsored and "Janssen Research & Development, LLC" with 3 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Quironsalud Barcelona" #1 collaborator was "AstraZeneca" with 3 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 3 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Effice Servicios Para la Investigacion S.L." with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Quironsalud Barcelona" are "Breast Cancer" (5 trials), "Metastatic Breast Cancer" (3 trials), "Atrial Fibrillation" (2 trials), "COVID-19" (2 trials) and "Chronic Kidney Disease" (2 trials). Many other conditions were trialed in "Hospital Quironsalud Barcelona" in a lesser frequency.

Most popular intervention types in "Hospital Quironsalud Barcelona" are "Drug" (31 trials), "Biological" (5 trials), "Other" (5 trials), "Device" (2 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Capecitabine" (3 trials), "Gemcitabine" (2 trials), "Nab-paclitaxel" (2 trials) and "Trastuzumab deruxtecan" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Quironsalud Barcelona" are 38 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Hospital Quironsalud Barcelona". undefined are not yet recruiting, 8 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Hospital Quironsalud Barcelona, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Quironsalud Barcelona, 5 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 3 trials that are defined as “Not Applicable".